Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LPO | P22079 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975825 | 0.85 | CA12 (0.42) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL378877 | 0.85 | CA12 (0.42) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL14382682 | 0.85 | CA12 (0.42) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL3866939 | 0.83 | MAOB (0.43) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL559965 | 0.83 | KDR (0.41) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL29851528 | 0.83 | KDR (0.41) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL4327915 | 0.83 | CA12 (0.44) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL560418 | 0.83 | CA12 (0.38) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL19745618 | 0.82 | CA12 (0.40) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL7706827 | 0.82 | CA1 (0.50) | CA12CA1CA9HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822349-B2 | Macrocyclic purines for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-03 | — | — | US | disclosed |
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-10-31 | — | — | US | disclosed |
| US-10280180-B2 | Macrocyclic purines for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150344936-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2015-10-22 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9151739-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | JNC CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | CA12 4782/4885CA1 4858/4885CA9 4649/4885 |
| US-20140296521-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | CA12 353/4885CA1 1491/4885CA9 562/4885 |
| US-10280180-B2 | Macrocyclic purines for the treatment of viral infections | PNP, HPRT1, UMPS | CA12 4782/4885CA1 4858/4885CA9 4649/4885 |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | CA12 353/4885CA1 1491/4885CA9 562/4885 |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | CA12 4782/4885CA1 4858/4885CA9 4649/4885 |
| US-10822349-B2 | Macrocyclic purines for the treatment of viral infections | PNP, HPRT1, UMPS | CA12 4782/4885CA1 4858/4885CA9 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.